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fragile X mental retardation protein (fMRp) binds to and regulates the translation of amyloid-β protein 
precursor (App) mRNA, but the detailed mechanism remains to be determined. Differential methylation 
of App mRNA could underlie FMRP binding, message localization and translation efficiency. We sought 
to determine the role of fMRp and n6-methyladeonsine (m6A) on nuclear export of App mRnA. We 
utilized the m6A dataset by Hsu and colleagues to identify m6A sites in App mRnA and to determine if 
the abundance of message in the cytoplasm relative to the nucleus is altered in Fmr1 knockout mouse 
brain cortex. Given that processing of App to Aβ and soluble App alpha (sAppα) contributes to disease 
phenotypes, we also investigated whether Fmr1KO associates with nuclear export of the mRnAs for 
App protein processing enzymes, including β-site amyloid cleaving enzyme (Bace1), A disintegrin 
and metalloproteinases (Adams), and presenilins (psen). Fmr1Ko did not alter the nuclear/cytoplasmic 
abundance of App mRNA. Of 36 validated FMRP targets, 35 messages contained m6A peaks but 
only Agap2 mRnA was selectively enriched in Fmr1KO nucleus. the abundance of the App processing 
enzymes Adam9 and Psen1 mRnA, which code for a minor alpha-secretase and gamma-secretase, 
respectively, were selectively enriched in wild type cytoplasm.
Reduced expression of fragile X mental retardation protein (FMRP) results in the neurodevelopmental disor-
der fragile X syndrome (FXS), which is characterized by intellectual disability, autistic-like behaviors and sei-
zures1. FMRP is an mRNA binding protein that binds to hundreds of mRNA ligands with dozens of these targets 
under study in relation to aberrant synaptic function and/or as drug targets for FXS2–9. A mouse model that 
lacks expression of FMRP has been generated (Fmr1KO mice) and serves as a surrogate for the study of FMRP 
function10. A major structure-function relationship of FMRP is that this RNA binding protein associates with the 
coding region sequence of transcripts and functions to stall ribosomal translocation11, albeit other functions have 
been identified including differential transport of methylated mRNA out of the nucleus9,12.
Methylation is a reversible modification involving the addition of methyl groups to DNA or RNA. In RNA, 
N6-methyladenosine (m6A) is the most abundant methylation modification in eukaryotes, accounting for more 
than 80% of RNA methylation. Fifteen percent of methylation consensus motifs are m6A modified with enrich-
ment at the 5’-UTR, near stop codons, in the 3’-UTR, and within long exons at an estimated average level of 
three m6A residues per mRNA13. RNA m6A modification occurs in the nucleus concurrent with transcription 
and serves as a chemical imprint that affects mRNA metabolism14. Specifically, mRNA m6A methylation has the 
potential to affect RNA folding, splicing, stability, sorting, transport, localization, storage, degradation and trans-
lation14–16. FMRP is a nucleocytoplasmic shuttling protein that binds mRNAs in the nucleus17, and has roles in 
many of the same aforementioned methylation-based functions. Thus, it is of interest to determine if methylation 
affects crosstalk between FMRP and its mRNA targets.
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Figure 1. Nuclear and cytoplasmic distribution of FMRP target mRNAs. Using the m6A-Seq dataset generated 
by Hsu and colleagues (Hsu Supplementary Table 5 18), RPKM values were extracted for nuclear and cytoplasmic 
fractions isolated from cortices of WT and Fmr1KO mice (postnatal day 11) and the mean expression level was 
plotted as response variable versus mouse genotype as predictor. Error bars represent standard error of the mean 
(SEM). Asterisks indicate statistical differences between nuclear and cytoplasmic compartments computed by 
2-way ANOVA with post-hoc Bonferroni multiple comparison tests (p < 0.050). Screened FMRP targets were 
previously reviewed9. Targets are presented in alphabetical order. See Figure 2 for the remaining targets.
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Figure 2. Nuclear and cytoplasmic distribution of FMRP target mRNAs. Using the m6A-Seq dataset generated 
by Hsu and colleagues (Hsu Supplementary Table 5 18), RPKM values were extracted for nuclear and cytoplasmic 
fractions isolated from cortices of WT and Fmr1KO mice (postnatal day 11) and the mean expression level was 
plotted as response variable versus mouse genotype as predictor. Error bars represent standard error of the mean 
(SEM). Asterisks indicate statistical differences between nuclear and cytoplasmic compartments computed by 
2-way ANOVA with post-hoc Bonferroni multiple comparison tests (p < 0.050). Screened FMRP targets were 
previously reviewed9. Targets are presented in alphabetical order. See Figure  1 for the remaining targets.
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Hsu and colleagues recently combined photoactivatable ribonucleoside-enhanced cross-linking and immuno-
precipitation (PAR-CLIP) with m6A immunoprecipitation (m6A-IP) to determine if FMRP binds directly to m6A 
methylation modifications on messenger RNA (mRNA)18. They demonstrated that FMRP binds directly to m6A 
sites in mRNAs, FMRP deletion increases nuclear m6A-mRNA levels, and the abundance of FMRP mRNA targets 
in the cytoplasm relative to the nucleus decreases in Fmr1KO mice18. These results strongly suggest that FMRP 
functions in the nuclear export of m6A-modified FMRP-target mRNAs.
The mRNA coding for amyloid-β precursor protein (APP) is an FMRP target. FMRP binds to a guanine-rich 
sequence in the coding region of both the mouse (App) and human (APP) variants of App mRNA and inhib-
its protein synthesis19,20. APP is the parent protein that is processed by secretases to produce amyloid-β (Aβ), 
which is the most prevalent protein found in the senile plaques of Alzheimer’s disease, as well soluble APP alpha 
(sAPPα), which is elevated in autism21–23. APP is dysregulated in Fmr1KO mice through a metabotropic glutamate 
receptor 5 (mGluR5)-dependent pathway, whereby activation of mGluR5 rapidly displaces FMRP from the coding 
region of App mRNA and thus increases translation of APP24. The detailed mechanism through which FMRP 
represses translation of APP remains to be determined.
We hypothesize that FMRP regulates localization, and hence protein synthesis of App mRNA through an 
m6A-dependent pathway. Furthermore, differential methylation of App mRNA, and not variations in FMRP lev-
els or activity, could explain cases of autism spectrum disorder that do not accompany FMRP aberrations. Thus, 
cross-talk between FMRP and m6A-App mRNA could have implications for FXS, Alzheimer’s disease, and autism. 
Here, we utilized the Supplementary Information provided by Hsu and colleagues to identify m6A sites in App 
mRNA and to determine if the abundance of message in the cytoplasm relative to the nucleus is altered in Fmr1 
knockout (KO) mouse brain cortex. Given that processing of APP may also contribute to disease-associated 
differences in the APP metabolites Aβ and sAPPα, we also investigated whether Fmr1KO associates with nuclear 
export of the mRNAs for APP processing enzymes, including β-site amyloid cleaving enzyme 1 (Bace1) and A 
disintegrin and metalloproteinases (Adam) 9, 10, and 17.
Results
The relative abundance of App mRNA in the cytoplasm versus the nucleus, based on RNAseq in cortical tissue 
from wild type (WT) and Fmr1KO C57BL/6 J mice (postnatal day 11), indicated significantly increased abundance 
of App mRNA in the cytoplasm that did not change in response to Fmr1 knockdown (Fig. 1, Supplementary 
Table S1). The reported data were in reads per kilobase per million (RPKM), which normalizes the RNAseq data 
for both sequencing depth and the length of the gene (Hsu Supplementary Information Table S518).
Genotype Location Animal




































KO Cytoplasm 1 53–2331210–1390
4.61
4.11
KO Cytoplasm 2 61–2331210–1398
4.71
4.55
Table 1. m6A Profiling of App mRNA in Mouse Cortexa. aData extracted from Hsu Supplementary Table 3 18.
Site Location Instancesa Log2 Enrichmentb Fold Enrichment
1: 84–211 start site 2/2/2/2 4.94 ± 0.32 24
2: 536–600 coding sequence 1/0/1/0 0.26 ± 0.17 0.07
3: 878–1017 coding sequence 0/1/1/0 1.15 ± 0.75 1.3
4: 1222–1390 coding sequence 2/2/2/2 4.11 ± 0.10 17
Table 2. App mRNA Average Log2 Enrichment ± SEM based on Table 1 data. aInstances are appearances for 
WT-nucleus/WT-cytoplasm/KO-nucleus/KO-cytoplasm, maximum 2 appearances per group. bMean values 
and SEM are calculated as if “missing sites” had a Log2 enrichment of zero.
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Methylation profiling of mouse cortical tissue identified multiple m6A sites in App mRNA (Table 1). There 
appears to be two highly reproducible m6A sites at 84–211 and 1222–1390, with additional sites at 536–600 and 
878–1017. The first m6A site encompasses the ATG start codon at position 150, and the other three sites are 
within the coding region of App mRNA (NM_001198823). The 878–1017 methylation site is immediately down-
stream of a near canonical G-quartet sequence in the coding region of App mRNA (position 825–846; X59379)19. 
The average Log2 enrichment was high for two of the four sites including the 84–211 site encompassing the start 
codon of App mRNA and the 1222–1390 site in the coding region (Table 2).
The majority of validated FMRP targets contained m6A sites, but Fmr1KO did not alter the abundance of these 
messages in the cytoplasm relative to the nucleus. Using the FMRP target list prepared by Sethna and colleagues9, we 
found that 35 out of 36 known FMRP target mRNAs (all but Sapap3/4 mRNA) contained m6A peaks (Figs. 1 and 2). 
In comparison, of the 24,661 screened mRNAs in the dataset, 12% did not contain any m6A peaks. The 35 
m6A-containing FMRP target mRNAs can be grouped based on nuclear and cytoplasmic localization. Twelve 
mRNAs including App mRNA had statistically significantly more message in the cytoplasm than the nucleus 
in both WT and Fmr1KO cortex. Five mRNAs had statistically significant more message in the nucleus com-
pared to the cytoplasm in both WT and Fmr1KO cortex. Eleven mRNAs did not differ between cytoplasm and 
nuclear localization in WT or Fmr1KO cortex. Four mRNAs (Dlg4, Mapk1, Pk3cb, and Pten) exhibited significantly 
increased cytoplasmic levels selectively in WT. Finally, one mRNA (Rps6kb1) exhibited significantly increased 
nuclear levels selectively in WT. Fmr1 mRNA levels were low in Fmr1KO cytoplasm. A single message (ArfGAP 
with GTPase domain; Agap2) was significantly enriched in the nucleus of Fmr1KO, suggesting that loss of FMRP 
reduced nuclear export. Only five mRNAs (Arc, Eef1a1, Fmr1, Gabrd, Shank3) exhibited genotype-specific differ-
ences by 2-way ANOVA (Supplementary Table S1).
The mRNAs for APP processing enzymes contained altered nuclear/cytoplasmic abundance as a function of 
Fmr1KO status. For Adam9 and Psen1, WT mRNA levels were significantly increased in the cyptoplasm versus 
Figure 3. Nuclear and cytoplasmic distribution of mRNAs coding for secretases (Adam9, Adam10, Adam17, 
and Bace1) mRNAs. Using the m6A-Seq dataset generated by Hsu and colleagues (Hsu Supplementary 
Table 5 18), RPKM values were extracted for nuclear and cytoplasmic fractions isolated from cortices of WT and 
Fmr1KO mice (postnatal day 11) and the mean expression level was plotted as response variable versus mouse 
genotype as predictor. Error bars represent standard error of the mean (SEM). Asterisks indicate statistical 
differences between nuclear and cytoplasmic compartments computed by 2-way ANOVA with post-hoc 
Bonferroni multiple comparison tests (p < 0.050).
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nucleus (Fig. 3, Supplementary Table S2). Fmr1KO reduced this difference to non-significant levels. Adam10 
mRNA levels did not differ by genotype or location. Levels of Adam17 mRNA were significantly lower in the 
cytoplasm compared to the nucleus for both WT and Fmr1KO animals. Levels of Bace1 and Psen2 mRNAs were 
significantly higher in cytoplasm than nucleus, but genotype did not exert a significant effect. Given the effects of 
Fmr1KO on Adam9 and Psen1 mRNA localization, we examined methylation profiling, which identified five m6A 
sites in both Adam9 (Tables 3 & 4) and Psen1 mRNAs (Tables 5 & 6). In Adam9 mRNA, four sites in the coding 
region were highly reproduced at position 62–184 (crossing start codon), 676–774, 1331–1392, and 2421–2503. 
The 1331–1392 site was immediately downstream of a GGACU element at nucleotide 1308. In Psen1 mRNA, 
three sites were highly reproduced at positions 456–616 (crossing start codon), 1474–1619 (coding sequence), 
and 2011–2172 (3’UTR). GGACU elements were located at positions 2014, 2025 and 2072 in the 3’-UTR.
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1: 62–184 start site 2/2/2/2 4.81 ± 0.38 23
2: 676–774 coding 2/2/1/2 1.53 ± 0.24 2.3
3: 1331–1392 coding 2/2/2/2 1.51 ± 0.13 2.3
4: 1819–2006 coding 0/1/0/0 0.18 ± 0.18 0.03
5: 2421–2503 coding 2/2/2/1 1.34 ± 0.21 1.8
Table 4. Adam9 mRNA Mean Log 2 Enrichment ± SEM based on Table 3 data. aInstances are appearances for 
WT-nucleus/WT-cytoplasm/KO-nucleus/KO-cytoplasm, maximum 2 appearances per group. bMean values 
and SEM are calculated as if “missing” sites had a Log2 enrichment of zero.
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Discussion
Methylation at m6A is the most abundant post-transcriptional mRNA modification in polyadenylated mRNAs 
and long non-coding RNAs in higher eukaryotes25. Recent findings indicate that FMRP target mRNAs contain an 
increased number of m6A peaks, mostly enriched in the coding regions of genes26, and that FMRP functions as an 
m6A reader protein that modulates neuron differentiation and mRNA stability through m6A-dependent mRNA 
mechanisms12,26–29. Out of 842 FMRP mRNA targets identified by Darnell and colleagues11, 95% had m6A modi-
fications in mouse brain cerebellum and 96% in cortex26. App mRNA is a validated FMRP target19.
App gene expression is negatively regulated by cytosine methylation30–32, but little is known regarding 
methylation-dependent regulation of App mRNA other than that small nuclear ribonucleoprotein (SNRP) splic-
ing factors regulate alternative splicing through a methylation-dependent mechanism17,33. To our knowledge, 
nuclear-cytoplasmic transport of App mRNA has not been reported34. Hsu and colleagues performed m6A-Seq in 
cytoplasmic and nuclear samples from P11 cortical tissue isolated from WT and Fmr1KO C57BL/6 J mice, and pro-
vided the normalized dataset as Supplementary Information to their manuscript18. Based on their global analysis 
of the dataset, they propose that FMRP is an m6A reader protein that binds directly to m6A sites in mRNA and 
functions in the export of those messages to the cytoplasm. This is an important phenomenon that could underlie 
FXS pathogenesis; thus, we wanted to determine if cross-talk between FMRP and m6A methylation affects the 
nuclear export of App mRNA.
We found that App mRNA contains four m6A sites and is more abundant in the cytoplasm relative to the 
nucleus. Fmr1KO did not alter the abundance of App mRNA in the cytoplasm or the nucleus suggesting that 
crosstalk between FMRP and m6A sites does not regulate nuclear-cytoplasmic transport of this message. It is not 
surprising that App mRNA levels were similar between WT and Fmr1KO samples as we previously demonstrated 
that App mRNA is a stable message and altered protein levels are not dependent on message decay19.
It is of interest that there is high enrichment of m6A in App mRNA in the region encompassing the start codon 
but not at the near canonical G-quartet region. RNAs that contain m6A can bind eukaryotic initiation factor 3 
(eIF3) without having a 5’-cap. This may facilitate additional cap-independent mRNA translation during cell 
stress35. In addition, the App m6A region that crosses the start codon also includes a nexus with an overlapping 
Genotype Location Animal










































Table 5. m6A Profiling of Psen1 mRNA in Mouse Cortexa. aData extracted from Hsu Supplementary Table 3 18. 
bThis RefSeq was removed from NCBI due to insufficient support for the transcript.
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interleukin-1 acute box, an iron response element and a target for microRNA-346, all of which may participate in 
neuronal iron (Fe) homeostasis36. The guanine-rich sequence in the coding region of App mRNA functions as a 
binding site for FMRP and heterogeneous nuclear ribonucleoprotein C (hnRNP C), which compete for binding 
and inversely regulate APP protein synthesis20. FMRP represses translation by recruiting App mRNA to process-
ing bodies whereas hnRNP C promotes translation by displacing FMRP20. It remains to be determined if m6A 
modification regulates App mRNA nuclear export through hnRNP C or other RBP, which may vary as a function 
of development and disease. PAR-CLIP previously identified three FMRP binding sites in APP mRNA (Ascano 
Supplementary Fig. 7: site 1: 888–948 in the coding region, site 2 in the coding region: 2169–2228, site 3 in the 
3’-UTR: 3337–3396)37. Site 1 overlaps with the guanine-rich site previously identified in mouse. The other two 
sites were not identified as m6A peaks in the Hsu dataset18. Overall, the findings indicate that FMRP does not 
regulate nuclear-cytoplasmic transport of App mRNA through an m6A-dependent pathway.
We further asked if the nuclear/cytoplasmic transport of other known FMRP targets or APP secretases were 
regulated by FMRP/m6A crosstalk. Of 36 validated FMRP targets9, 35 messages contained m6A peaks. Several 
FMRP target mRNAs (Dlg4, Mapk1, Pik3cb, Pten and Rps6kb1) exhibited significantly altered nuclear/cytoplas-
mic distribution in WT samples, but there were trends for the same phenomenon in the Fmr1KO, suggesting 
that FMRP/m6A crosstalk does not play a prominent role in nuclear transport of these messages. Only Agap2 
mRNA was selectively enriched in Fmr1KO nucleus suggesting that loss of FMRP reduced its nuclear export. 
Agap2 mRNA codes for phosphoinositide-3 kinase enhancer (PIKE) protein, which is an important regulator of 
group 1 mGluR-dependent phosphoinositide-3 kinase (PI3K) activity38,39. The gene for Agap2 is highly enriched 
in key pathways involved in amyloid-beta formation, the regulation of cardiocyte differentiation, and in actin 
cytoskeleton reorganization40. The Agap2 promoter is hypermethylated in Alzheimer’s disease41. Agap2 mRNA 
was not included in the Edupuganti pulsed-SILAC translation dataset29, suggesting that FMRP regulates nuclear 
export but not protein synthesis. Of the 36 validated FMRP mRNA targets reviewed by Sethna and colleagues9, 






1: 347–434 5’-UTR 1/2/0/1 1.74 ± 0.66 3.0
2: 456–616 start site 2/2/2/2 2.60 ± 0.087 6.8
3. 639–758 coding 1/0/0/1 0.35 ± 0.23 0.12
4. 1474–1619 coding 2/2/2/2 1.94 ± 0.10 3.8
5. 2011–2172 3’-UTR 2/2/2/2 5.68 ± 0.16 32
Table 6. Psen1 mRNA Mean Log 2 Enrichment ± SEM based on Table 5 data. aInstances are appearances for 
WT-nucleus/WT-cytoplasm/KO-nucleus/KO-cytoplasm, maximum 2 appearances per group. bMean values 
and SEM are calculated as if “missing” sites had a Log2 enrichment of zero. UTR = untranslated region.
Figure 4. Potential function of FMRP in regulating the transport of Adam9 and Psen1 mRNA into the 
cytoplasm. (A) Under normal conditions, FMRP recognizes m6A sites on multiple mRNAs, including Adam9 
and Psen1, and interacts with the mRNA transport machinery (not shown). Transported mRNAs are available 
for protein synthesis resulting in normal levels of ADAM9 and PSEN1 protein and normal APP processing. 
(B) The absence of FMRP leads to reduced transport of m6A-marked mRNAs, potentially reducing levels of 
ADAM9 and PSEN1 proteins. While ADAM10 activity may compensate, disruption of the gamma-secretase 
complex may result in subtle cell dysfunction.
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Adam9 mRNA, which encodes for a minor α-secretase, as well as Psen1 mRNA, which codes for gamma 
secretase, were selectively reduced in the nucleus of WT samples but not Fmr1 knockouts, suggesting that 
FMRP may play a role in cytoplasmic transport of these secretase coding mRNAs (Fig. 4). This finding is unex-
pected in light of western blot data showing equal ADAM9 protein levels between WT and Fmr1KO and lack of 
FMRP/Adam9 mRNA co-immunoprecipitation42 even though Adam9 mRNA possess a near canonical G-quartet 
(DWGGN0–2DWGGN0–1DWGGN0–1DWGG)7 at position 3756 in the 3’-UTR (TAGG_CT_GGAG_A_AAGG_
AAGG) (NM_001270996). Deletion of ADAM9 does not appreciably alter levels of α-secretase processing of 
APP43, but this may be due to compensatory upregulation of ADAM1044. An in-depth investigation of ADAM9 
protein or mRNA levels in human subjects with APP-related disorders, such as Alzheimer’s disease and autism 
spectrum disorder, has yet to be performed. It may be possible that ADAM9 disruption functions in some but not 
all APP-related disorders.
Overall, the main findings of this study were that FMRP/m6A crosstalk does not mediate the nuclear export of 
App mRNA nor export of the majority of other validated FMRP target mRNAs, but does affect the nuclear export 
of mRNAs for two APP secretases, Adam9 and Psen1. The function of m6A sites in Adam9 and Psen1 messages 
remains to be determined. Specifically, mRNA methylation has the potential to affect RNA folding, splicing, 
stability, sorting, transport, localization, storage, degradation and/or translation14–16. Disruption of ADAM9 func-
tion could play a role in some but not all APP-related disorders. Further investigation of ADAM9, AGAP2 and 
PSEN1 levels in human subjects with APP-related disorders could help in understanding Alzheimer’s disease 
and autism spectrum disorders. It also remains to be determined how the binding and activity of other RBP are 
affected by m6A methylation and if m6A methylation is altered as a function of development and environment. 
The limitation of this study is the dataset is dependent on one time point, which precludes analysis as a function 
of development and disease severity. The strengths of the study are the large dataset, nuclear/cytoplasmic distri-
bution data in quadruplicate, and utilization of the most widely used FXS model.
Methods
Dataset: We utilized the m6A dataset generated by Hsu and colleagues, which is available online at http://www.
jbc.org/content/294/52/19889.long, to extract data regarding m6A modifications to App, Adam9 and Psen1 
mRNAs (Hsu Supplementary Table 318) as well as FMRP target mRNA nuclear/cytoplasmic distributions (Hsu 
Supplementary Table 5 18). The Hsu dataset was generated by performing RNA isolation and m6A-Seq on nuclear 
and cytoplasmic fractions isolated from cortices of wild type (WT) and Fmr1KO mice in the C57BL/6 J back-
ground (postnatal day 11). m6A-Seq data were available for 23,869 mRNAs and nuclear/cytoplasmic distribution 
data were available for 24,661 mRNAs. m6A-Seq was performed in duplicates and nuclear/cytoplasmic distribu-
tion in quadruplicate.
Analyses: Data were analyzed in accordance with STROBE guidelines (https://strobe-statement.org/index.php
?id=available-checklists). Means, standard deviations from the mean (SEM), and 2-way ANOVA with post-hoc 
Bonferroni multiple comparison tests were computed to describe the results. Statistical significance was defined 
as p < 0.050.
Data availability
All materials and data associated with the manuscript are or will be made available to readers by contacting the 
corresponding author.
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